Sugi Predict

Sugi Predict / Compounds / SCHEMBL6672350

SCHEMBL6672350

SCHEMBL6672350

COc1ccc(CCl)cc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.60
▸ MAPK1 P28482 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ HTT P42858 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ ABCB1 P08183 2/20 0.57
▸ ABCG2 Q9UNQ0 1/20 0.57
▸ KMT2A Q03164 2/20 0.56
▸ NPY1R P25929 1/20 0.56
▸ NPY2R P49146 1/20 0.56
▸ BCHE P06276 1/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ SMPD1 P17405 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11093699 0.98 TTR (0.59) TTRMAPK1HSD17B10KDM4ELMNA
Phosphine SCHEMBL4434544 0.98 TTR (0.59) TTRMAPK1HSD17B10KDM4ELMNA
SCHEMBL5387584 0.94 TTR (0.65) TTRHSD17B10KDM4ELMNASMN1; SMN2
SCHEMBL25253735 0.92 TTR (0.52) TTRMAPK1HSD17B10KDM4ELMNA
SCHEMBL29463715 0.92 TTR (0.52) TTRMAPK1HSD17B10KDM4ELMNA
SCHEMBL2074825 0.90 SLC2A1 (0.52) TTRMAPK1HSD17B10KDM4ELMNA
SCHEMBL29463780 0.86 TTR (0.56) TTRHSD17B10KDM4ELMNASMN1; SMN2
SCHEMBL25292206 0.86 TTR (0.56) TTRHSD17B10KDM4ELMNASMN1; SMN2
SCHEMBL8554822 0.85 MAPK1 (0.64) MAPK1HSD17B10KDM4ELMNAHTT
SCHEMBL8554816 0.84 MAPK1 (0.59) MAPK1HSD17B10KDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102791667-B Method for producing high purity aromatic methyl alcohol, and high purity aromatic methyl alcohol composition having excellent storage stability UBE INDUSTRIES 2014-11-05 — — CN disclosed
EP-2540695-A1 METHOD FOR PRODUCING HIGH PURITY AROMATIC METHYL ALCOHOL, AND HIGH PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT STORAGE STABILITY Ube Industries, Ltd. (JP) 2013-01-02 — — EP disclosed
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY UBE INDUSTRIES, LTD. (JP) 2012-12-20 — — US disclosed
CN-102791667-A Method for producing high purity aromatic methyl alcohol, and high purity aromatic methyl alcohol composition having excellent storage stability UBE INDUSTRIES 2012-11-21 — — CN disclosed
US-6818642-B2 CAMPYLOBACTER INFECTION TREATMENT ALTANA PHARMA AG (DE) 2004-11-16 — — US disclosed
EP-1202628-B1 NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS EURO CELTIQUE SA (LU) 2004-10-13 — — EP disclosed
US-20040152714-A1 Benzylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-05 — — US disclosed
EP-1395594-A1 NEW BENZYLAMINOPYRIMIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2004-03-10 — — EP disclosed
CN-1122669-C Novel 8H-thiophene [2,3-b] pyrrolinezine-8-on compound, its preparing method and their medicinal compounds containing them ADIR (FR) 2003-10-01 — — CN disclosed
EP-1045849-B1 PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY EURO CELTIQUE SA (LU) 2003-07-02 — — EP disclosed
US-6228859-B1 ANTIASTHMATIC, ANTIINFLAMMATORY, ANTIALLERGEN AND ANTIDEPRESSANT AGENTS EURO-CELTIQUE S.A. (LU) 2001-05-08 — — US disclosed
WO-2001011967-A1 NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS EURO-CELTIQUE S.A. (LU) 2001-02-22 — — WO disclosed
EP-1045849-A1 PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY Euro-Celtique S.A. (LU) 2000-10-25 — — EP disclosed
EP-0982308-A1 Derivatives of the 8H-(2,3-b)-pyrrolizine-8-one, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2000-03-01 — — EP disclosed
WO-1999031102-A1 PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY EURO-CELTIQUE, S.A. (LU) 1999-06-24 — — WO disclosed
EP-0613879-A1 PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT TSUMURA & CO. (JP) 1994-09-07 — — EP disclosed
EP-0046710-B1 PREPARATION OF AMINOACETONITRILE DERIVATIVES MERRELL TORAUDE ET COMPAGNIE (FR) 1984-06-13 — — EP disclosed
US-4405530-A Process for preparing fluorinated amino-nitriles MERRELL TORAUDE ET COMPAGNIE (FR) 1983-09-20 — — US disclosed
US-4342780-A 2-AMINO-2-FLUOROMETHYL-3-(SUBSTITUTED) PHENYL PROPIONIC ACIDS AND DERIVATIVES COADMINISTERED WITH DOPAMINE MERRELL-TORAUDE ET CIE (FR) 1982-08-03 — — US disclosed
EP-0046710-A1 Preparation of aminoacetonitrile derivatives MERRELL TORAUDE ET COMPAGNIE (FR) 1982-03-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152714-A1 Benzylaminopyrimidines DPYD, PGLS, TPMT TTR 2305/4885MAPK1 1491/4885HSD17B10 1494/4885
US-20120323021-A1 METHOD FOR PRODUCING A HIGH-PURITY AROMATIC METHYL ALCOHOL AND HIGH-PURITY AROMATIC METHYL ALCOHOL COMPOSITION HAVING EXCELLENT PRESERVATION STABILITY ALKBH5, ALKBH2, ALKBH3 TTR 1712/4885MAPK1 3637/4885HSD17B10 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.